Hormonal
GLP-1 receptor agonists (e.g., liraglutide, semaglutide, tirzepatide) significantly reduce body weight and improve glycemic control in patients with Type 2 Diabetes and Obesity.
GLP-1 receptor agonists are highly effective for weight loss and blood sugar control in obesity and Type 2 Diabetes. Options include daily or weekly injections and oral tablets. Expect significant weight loss (15-24% depending on the drug) and improved metabolic health. Discuss specific drug choice (e.g., Semaglutide vs. Tirzepatide) with your doctor based on efficacy needs and administration preference.
Während Liraglutid noch tägliche Injektionen erforderte, da es schnell durch Peptidasen metabolisiert wird, muss Semaglutid nur einmal wöchentlich injiziert werden. [...] Während die herkömmlichen GLP-1-Rezeptoragonisten zu einem Gewichtsverlust von ca. 15 % führen, erreicht Tirzepatid bei einer wöchentlich injizierten Dosis von 10 mg oder 20 mg einen Gewichtsverlust von ~20 % [4]. Retratrutid [...] führt sogar zu durchschnittlich 24 % (~26 kg) Gewichtsverlust innerhalb von 48 Wochen, verglichen mit 2 % unter Placebo [5].
Why this rating
Supported by multiple RCTs and meta-analyses cited in the text.
Source
Glucagon-like-peptide-1-Rezeptoragonisten: eine neue pharmakologische Behandlungsoption für psychiatrische Erkrankungen?
Hubertus Himmerich · Der Nervenarzt · 2025
DOI 10.1007/s00115-025-01813-x
More from this paper
- GLP-1 receptor agonists are associated with gastrointestinal side effects (nausea, vomiting, diarrhea) and potentially increased risks of pancreatitis and thyroid cancer.Strong
- GLP-1 receptor agonists show potential therapeutic benefits for psychiatric conditions, including depression, anxiety, binge-eating disorder, and substance use disorders, though evidence quality varies.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →